Kazia says glioblastoma trial data won’t support FDA accelerated nod for lead drug
[ad_1]
Kazia says glioblastoma trial data won’t support FDA accelerated nod for lead drug
[ad_2]
Similar Posts
Danimer Scientific to delist from NYSE
Byadmin
[ad_1] Danimer Scientific to delist from NYSE [ad_2]
Arhaus raises FY 2024 revenue outlook; CFO steps down
Byadmin
[ad_1] CreativaStudio/E+ via Getty Images Arhaus (NASDAQ:ARHS) raised its net revenue expectations for full year 2024 to $1.27 billion to $1.28 billion, an increase of approximately $35 million versus prior expectations. While comparable growth is expected to decline between 9% to 8%. Outlook [ad_2]
BlackRock ESG Capital Allocation Trust declares $0.3074 dividend
Byadmin
[ad_1] BlackRock ESG Capital Allocation Trust declares $0.3074 dividend [ad_2]
Yoshiharu jumps 30%, raises $11M to support expansion plans
Byadmin
[ad_1] Yoshiharu jumps 30%, raises $11M to support expansion plans [ad_2]
Commvault Systems initiated with Overweight rating at KeyBanc
Byadmin
[ad_1] Commvault Systems initiated with Overweight rating at KeyBanc [ad_2]
Diversity in the Workplace: Importance and Benefits
Byadmin
[ad_1] In today’s globalized world, diversity has become indispensable for business success. But what exactly constitutes a diverse workplace? Why is diversity so crucial? Let’s explore what workplace diversity means, why it matters, and how to cultivate it. What is Diversity in the Workplace? Workplace diversity refers to having employees from a wide range of…